Cherrington JM - Search Results

1

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Potapova O, et al. Among authors: cherrington jm. Mol Cancer Ther. 2006 May;5(5):1280-9. doi: 10.1158/1535-7163.MCT-03-0156. Mol Cancer Ther. 2006. PMID: 16731761

2

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.

Laird AD, Cherrington JM. Laird AD, et al. Among authors: cherrington jm. Expert Opin Investig Drugs. 2003 Jan;12(1):51-64. doi: 10.1517/13543784.12.1.51. Expert Opin Investig Drugs. 2003. PMID: 12517254 Review.

3

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. Mendel DB, et al. Among authors: cherrington jm. Clin Cancer Res. 2003 Jan;9(1):327-37. Clin Cancer Res. 2003. PMID: 12538485

4

Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.

Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, Mendel DB. Laird AD, et al. Among authors: cherrington jm. Mol Cancer Ther. 2003 May;2(5):461-9. Mol Cancer Ther. 2003. PMID: 12748308

5

Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.

Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Moss KG, et al. Among authors: cherrington jm. J Pharmacol Exp Ther. 2003 Nov;307(2):476-80. doi: 10.1124/jpet.103.052530. Epub 2003 Sep 9. J Pharmacol Exp Ther. 2003. PMID: 12966161

6

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. Patyna S, et al. Among authors: cherrington jm. Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. Mol Cancer Ther. 2006. PMID: 16891463

7

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM. Mendel DB, et al. Among authors: cherrington jm. Anticancer Drug Des. 2000 Feb;15(1):29-41. Anticancer Drug Des. 2000. PMID: 10888034 Review.

8

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.

Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM. Laird AD, et al. Among authors: cherrington jm. FASEB J. 2002 May;16(7):681-90. doi: 10.1096/fj.01-0700com. FASEB J. 2002. PMID: 11978732

9

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Liao AT, et al. Among authors: cherrington jm. Blood. 2002 Jul 15;100(2):585-93. doi: 10.1182/blood-2001-12-0350. Blood. 2002. PMID: 12091352 Free article.

10

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB. Christensen JG, et al. Among authors: cherrington jm. Cancer Res. 2003 Nov 1;63(21):7345-55. Cancer Res. 2003. PMID: 14612533

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters